Palbociclib

Major

Palbociclib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Palbociclib Abametapir Explained Increased exposure of CYP3A4 substrate Details Palbociclib Clindamycin ANTIROBE Explained Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Omeprazole Gastrobim Explained Reduced efficacy of palbociclib Details Palbociclib Buprenorphine Belbuca Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Palbociclib Colchicine Colcrys Explained Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Abemaciclib Verzenio Explained Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Acalabrutinib Calquence Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Atorvastatin Atorvaliq Increased atorvastatin exposure Details Palbociclib Axitinib Inlyta Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Bedaquiline Sirturo Increased bedaquiline exposure Details Palbociclib Bosutinib Bosulif Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Brigatinib Alunbrig Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Budesonide Entocort Increased budesonide exposure Details Palbociclib Budesonide Nasal Spray Rhinocort Increased budesonide exposure Details Palbociclib Budesonide Oral Inhalation Pulmicort Increased budesonide exposure Details Palbociclib Clindamycin Injection ANTIROBE Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Clindamycin Topical C/T/S® Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Clindamycin Vaginal Cleocin Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Cobimetinib Cotellic Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Cyclosporine Injection Atopica Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Cyclosporine Ophthalmic Cequa Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Dasatinib Phyrago Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Dexlansoprazole Dexilant Reduced efficacy of palbociclib Details Palbociclib Dihydroergotamine Injection DHE-45® Injection Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Dihydroergotamine Nasal Spray Migranal Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Docetaxel Beizray Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Docetaxel Injection Beizray Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Dofetilide Tikosyn Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Palbociclib Entrectinib Rozlytrek Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Esomeprazole Nexium Reduced efficacy of palbociclib Details Palbociclib Esomeprazole Injection Nexium Reduced efficacy of palbociclib Details Palbociclib Everolimus Afinitor Increased exposure to CYP3A substrates with a narrow therapeutic index Details Palbociclib Fentanyl Transdermal Patch Duragesic® Increased fentaNYL exposure and an increased risk of prolonged opioid effects Details Palbociclib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Palbociclib Ketoconazole Topical Extina® Foam Increased palbociclib exposure Details Palbociclib Lansoprazole Prevacid Reduced efficacy of palbociclib Details Palbociclib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Palbociclib Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details